Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 8;23(1):495.
doi: 10.1186/s12890-023-02755-3.

The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials

Amin Daei Sorkhabi  1 , Mahta ZareDini  2 , Asra Fazlollahi #  2 , Aila Sarkesh #  1 , Amirreza Naseri  3 , Seyed Ehsan Mousavi  4   5 , Seyed Aria Nejadghaderi  6   7 , Mark J M Sullman  8   9 , Ali-Asghar Kolahi  10 , Saeid Safiri  11   12
Affiliations

The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials

Amin Daei Sorkhabi et al. BMC Pulm Med. .

Abstract

Background: Tislelizumab is an anti-programmed death-1 (PD-1) monoclonal antibody with a construction that enables it to have a higher affinity to its target. We aimed to evaluate tislelizumab's safety and efficacy for treating non-small cell lung cancer (NSCLC).

Methods: Embase, Scopus, PubMed, Web of Science, and Google Scholar were searched up to December 20, 2022. The review only included randomized controlled trials (RCTs) that evaluated the safety or efficacy of tislelizumab for treating patients with lung cancer. The revised Cochrane risk-of-bias tool (RoB2) was utilized to evaluate study quality.

Results: There were four RCTs identified, which included 1565 patients with confirmed locally advanced or metastatic squamous and/or non-squamous types of NSCLC. Treatment with tislelizumab was associated with better progression-free survival (PFS) and objective response rate (ORR), particularly when used in combination with chemotherapy. Almost all patients in both arms reported at least one treatment-emergent adverse event (TEAE). Decreased hematologic indexes accounted for more than 20% of the grade ≥ 3 TEAEs in the tislelizumab plus chemotherapy group. The proportion of TEAE that led to death in the tislelizumab plus chemotherapy arms ranged from 3.2 to 4.2%. Hypothyroidism, pneumonitis, and hyperglycemia were the most frequently noted immune-mediated adverse events in the tislelizumab group.

Conclusions: Tislelizumab, whether used alone or in combination with chemotherapy, seems to demonstrate both a safety and efficacy as a treatment for NSCLC.

Keywords: Anti-PD-1 monoclonal antibody; Immune checkpoint inhibitors; Lung Cancer; NSCLC; Systematic review; Tislelizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

No conflict of interest declared.

Figures

Fig. 1
Fig. 1
Study selection process
Fig. 2
Fig. 2
Summary of the risk of bias assessments for the included studies
See this image and copyright information in PMC

References

    1. Schabath MB, Cote ML. Cancer Progress and priorities: Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1563–79. doi: 10.1158/1055-9965.EPI-19-0221. - DOI - PMC - PubMed
    1. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Jr, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. doi: 10.1016/S0140-6736(16)30958-8. - DOI - PubMed
    1. Shahverdi M, Hajiasgharzadeh K, Sorkhabi AD, Jafarlou M, Shojaee M, Jalili Tabrizi N, et al. The regulatory role of autophagy-related miRNAs in Lung cancer drug resistance. Biomed Pharmacother. 2022;148:112735. doi: 10.1016/j.biopha.2022.112735. - DOI - PubMed
    1. Alam K, Rahman M, Beg S, Chauhan D, Hafeez A, Almalki WH, et al. et al. Chapter 5 - Advancement in protein-based nanocarriers in targeted anticancer therapy. In: Rahman M, Beg S, Almalki WH, Alhakamy NA, Choudhry H, et al.et al., editors. Nanotherapeutics in Cancer Vaccination. and Challenges: Academic Press; 2022. pp. 95–102.
    1. Sharma P, Mehta M, Dhanjal DS, Kaur S, Gupta G, Singh H, et al. Emerging trends in the novel drug delivery approaches for the treatment of Lung cancer. Chem Biol Interact. 2019;309:108720. doi: 10.1016/j.cbi.2019.06.033. - DOI - PubMed

Publication types

MeSH terms

Substances